196. Weight Loss Pharmacology for the RDN: Safety and Efficacy

FNCE Recorded Sessions from 2017

More than two-third of adults and almost one-third of children and adolescents in the United States are overweight or obese.

  • SKU FNCE17196
Member Price
$32.00
Nonmember Price
$37.00

This product is free for those who attended FNCE® 2017.

More than two-third of adults and almost one-third of children and adolescents in the United States are overweight or obese. Overweight and obesity are linked to heart disease, stroke, type 2 diabetes and certain types of cancer. RDNs are working on the forefront with individuals to help change behaviors to reduce weight. Clients seeking weight loss may also use prescription medications or dietary supplements to aid in weight loss. RDNs working with overweight or obese clients must understand the safety and efficacy of these products, their proposed mechanisms for promoting weight loss, and the amount of weight loss that can be expected with these agents. This knowledge can help the RDN provide insightful dietary advice tailored to each patient's specific needs and goals. Discussing the role of these modalities in weight loss, without projecting judgment, will contribute to honest and productive communication between the patient and the dietitian.

CPEU: 1.5
CPE Level: 2
Learning Codes: 3070, 5370, 6020

Learning Objectives

  • List available prescription medications labeled for weight loss, briefly describe the expected amount of weight loss associated with each agent; and discuss key side effects or safety concerns with each agent.
  • Describe safety and effectiveness data specific to a few popular dietary supplements used for weight loss.
  • Discuss medications and dietary supplements for weight loss with patients in a knowledgeable and nonjudgmental way to help the patient set realistic goals for weight loss and facilitate realization of these goals.

Speaker

  • David Peterson, PharmD
  • Lacie Peterson, MS, RD, CDE

Moderator

  • Nikki Kendrick, MDA, RDN, CNSC
  • SKU FNCE17196